| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.1 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.1 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.083 | 0.1 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.1 |